7391-69-7

Basic information

• Product Name: 5-ISOPROPYLBARBITURIC ACID
• Synonyms: 5-ISOPROPYLBARBITURIC ACID;3-ISOPROPYLBARBITURIC ACID;ISOPROPYLBARBITURIC ACID;2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-;5-ISOPROPYLBARBITURIC;5-Isopropyl-2,4,6(1H,3H,5H)-pyrimidinetrione;Einecs 230-982-8;5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione
• CAS NO: 7391-69-7
• Molecular Formula: C₇H₁₀N₂O₃
• Molecular Weight: 170.17
• EINECS: 230-982-8
• Mol File: 7391-69-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 213-216°C
• Boiling Point: 299.79°C (rough estimate)
• Appearance: /
• Density: 1.3173 (rough estimate)
• Refractive Index: 1.4880 (estimate)
• PKA: pK1:4.907(＋1) (25°C)
• Water Solubility: 5.925g/L(20 oC)
• BRN: 149805
• CAS DataBase Reference: 5-ISOPROPYLBARBITURIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ISOPROPYLBARBITURIC ACID(7391-69-7)
• EPA Substance Registry System: 5-ISOPROPYLBARBITURIC ACID(7391-69-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 7391-69-7(Hazardous Substances Data)

Usage

General Description

5-Isopropylbarbituric acid, also known as phenobarbital, is a barbiturate medication that acts as a central nervous system depressant. It is commonly used to treat seizures, insomnia, and anxiety. The chemical works by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, resulting in a calming effect and reduced brain activity. It is available in various forms, including tablets, capsules, and injections, and is typically taken orally. 5-Isopropylbarbituric acid has the potential for abuse and dependence and should be used with caution, especially in individuals with a history of substance abuse or addiction. Side effects may include drowsiness, dizziness, and respiratory depression, and it should not be used in combination with alcohol or other central nervous system depressants.

InChI:InChI=1/C7H10N2O3/c1-3(2)4-5(10)8-7(12)9-6(4)11/h3-4H,1-2H3,(H2,8,9,10,11,12)

Upstream product

• 759-36-4 diethyl isopropylmalonate 
• 67-52-7 BARBITURIC ACID 
• 67-64-1 acetone 
• 57-13-6 urea 
• 64-17-5 ethanol 
• 98546-82-8 5-chloro-5-isopropyl-barbituric acid 
• 16952-71-9 5-bromo-5-isopropyl-barbituric acid 
• 75-26-3 isopropyl bromide 
• 105-53-3 diethyl malonate 

Downstream Products

• 1146-21-0 5-FU 
• 545-93-7 5-(2-bromoallyl)-5-isopropylbarbituric acid 
• 77-02-1 aprobarbital 
• 17432-95-0 5-isopropyluracil 
• 41333-98-6 4-(5-isopropyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylazo)-N-thiazol-2-yl-benzenesulfonamide 
• 41334-03-6 4-(5-isopropyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylazo)-N-(4-methyl-thiazol-2-yl)-benzenesulfonamide 
• 41334-07-0 N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-4-(5-isopropyl-2,4,6-trioxo-hexahydro-pyrimidin-5-ylazo)-benzenesulfonamide 
• 1780-42-3 2,4,6-trichloro-5-isopropylpyrimidine 
• 176519-55-4 6-benzyl-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 172256-08-5 6-[(3,5-dimethylphenyl)selenenyl]-1-(ethoxymethyl)-5-isopropyluracil 
• 172256-31-4 1-[(benzyloxy)methyl]-6-chloro-5-isopropyluracil 

Relevant articles and documents

NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto． (I), (Ia)

Synthesis and antimicrobial activity of some novel 5-alkyl-6-substituted uracils and related derivatives

6-Chloro-5-ethyl-, n-propyl- and isopropyluracils 5a-c were efficiently prepared from the corresponding 5-alkybarbituric acids 3a-c via treatment with phosphorus oxychloride and N,N-dimethylaniline to yield the corresponding 5-alkyl-2,4,6-trichloropyrimidines 4a-c, which were selectively hydrolyzed by heating in 10% aqueous sodium hydroxide for 30 minutes. The reaction of compounds 5a-c with 1-substituted piperazines yielded the corresponding 5-alkyl-6-(4-substituted-1-piperazinyl)uracils 6a-j. The target 8-alkyltetrazolo[1,5-f]pyrimidine-5,7(3H,6H)-diones 7a-c were prepared via the reaction of 5a-c with sodium azide. Compounds 6a-j and 7a-c were tested for in vitro activities against a panel of Gram-positive and Gram-negative bacteria and the yeast-like pathogenic fungus Candida albicans. Compound 6h displayed potent broad-spectrum antibacterial activity, while compound 6b showed moderate activity against the Gram-positive bacteria. All the tested compounds were practically inactive against Candida albicans.

Non-nucleoside HIV-1 reverse transcriptase inhibitors, part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues

A series of novel 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) analogues bearing a 6-(1-naphthoyl) group of non-nucleoside human immunodeficiency virus (HIV) reverse transcriptase inhibitors were synthesized and evaluated for their activity against HIV-1 and HIV-2. It was found that most of these compounds showed good activity against HIV-1. Among them, compound 5-isopropyl-6-(1-naphthoyl)-1-[(2E)-3-phenylallyl]-2,4-pyrimidinedione (23) displayed the greatest inhibitory potency (IC50=0.14 μM), which is about 35-fold more active than HEPT and DDI. To rationalize the relationships between structure and activity of these novel compounds, a three-dimensional quantitative structure-activity relationship (3D-QSAR) model was also generated. The results provided a tool for guiding the further design of more potent antiviral agents and for predicting the affinity of related compounds.